4.6 Article

Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection

Journal

JOURNAL OF IMMUNOLOGY
Volume 189, Issue 6, Pages 3054-3063

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1200701

Keywords

-

Categories

Funding

  1. Albert Einstein College of Medicine
  2. National Institutes of Health [DP2DK083076, AI R01-AI045459, R01-AI044374, T32DK007513, T32DK007218, AI-51519]
  3. Department of Defense [PC094137]

Ask authors/readers for more resources

B7x (B7-H4 or B7S1), a member of the B7 family, inhibits in vitro T cell proliferation and cytokine production by binding to an unidentified receptor on activated T cells, but its in vivo function remains largely unclear. We show that B7x protein was expressed in epithelial cells of the lung, but not in lymphoid tissues. To investigate the role of B7x in the lung, we determined the susceptibility of B7x-deficient (B7x(-/-)) mice to a lethal pulmonary infection with Streptococcus pneumoniae. B7x(-/-), but not B7-H3-deficient, mice were significantly more resistant to S. pneumoniae pulmonary infection than their wild-type (Wt) counterparts. B7x(-/-) mice had significantly lower bacterial burdens and levels of inflammatory cytokines in lungs as early as 12 h postinfection. They also had milder immunopathology that was localized in alveolar spaces, whereas Wt mice had severe inflammation that was perivascular. Control of infection in B7x(-/-) mice was associated with a marked increase in activated CD4 and CD8 T cells and fewer neutrophils in lungs, whereas the susceptible Wt mice had the opposite cellular profile. In B7x(-/-) Rag1(-/-) mice that lack T cells, reduction in bacterial burden was no longer observed. Control of S. pneumoniae and the increased survival observed was specific to the lung, because systemically infected B7x(-/-) mice were not resistant to infection. These data indicate that lung-expressed B7x negatively regulates T cells, and that in its absence, in B7x(-/-) mice, an enhanced T cell response contributed to reduced lethality in a pulmonary infection model with S. pneumoniae. The Journal of Immunology, 2012, 189:3054-3063.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis

Patrick P. C. Boor, Kostandinos Sideras, Katharina Biermann, M. Hosein Aziz, Iris J. M. Levink, Shanta Mancham, Nicole S. Erler, Xudong Tang, Casper H. van Eijck, Marco J. Bruno, Dave Sprengers, Xingxing Zang, Jaap Kwekkeboom

BRITISH JOURNAL OF CANCER (2020)

Article Cell Biology

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma

Zhen Zhang, Jinyan Liu, Chaoqi Zhang, Feng Li, Lifeng Li, Dan Wang, Damini Chand, Fangxia Guan, Xingxing Zang, Yi Zhang

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Article Cell Biology

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer

Yuxin Li, Yao Liu, Na Zhao, Xiaojun Yang, Yaqing Li, Fangzheng Zhai, Xingxing Zang, Wei Cui

CELL DEATH & DISEASE (2020)

Article Oncology

B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors

Ziqiang Yuan, Juliet C. Gardiner, Elaine C. Maggi, Shuyu Huang, Asha Adem, Svetlana Bagdasarov, Guiying Li, Sylvia Lee, Daniel Slegowski, Alyssa Exarchakis, James R. Howe, Edmund C. Lattime, Xingxing Zang, Steven K. Libutti

Summary: The study found that HHLA2 and B7x are highly expressed in GINETs and PNETs, and correlate with malignancy and spread. The overexpression of HIF-1 alpha is associated with the upregulation of B7x, and Men1/B7x double knockout mice show increased T-cell infiltration. Targeting B7x may offer a promising strategy for immunotherapy in patients with NETs.

ENDOCRINE-RELATED CANCER (2021)

Article Oncology

Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance

Phillip M. Galbo, Xingxing Zang, Deyou Zheng

Summary: This study conducted a comprehensive analysis of CAFs from multiple cancer types, identified shared molecular characteristics in CAF subtypes, and revealed the association of different CAF subtypes with clinical outcomes and immunotherapy resistance.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer

Wei Zhang, Ana Acuna-Villaorduna, Kevin Kuan, Sorab Gupta, Shaomin Hu, Kim Ohaegbulam, Joseph Albanese, Meghan Kaumaya, Rachel Levy, Richard R. Hwang, Xingxing Zang, Juan Lin, Qiang Liu, Radhashree Maitra, Sanjay Goel

Summary: Low expression of both PD-L1 and B7-H3 in colorectal cancer is associated with better survival outcomes, without significant variation among different racial groups in terms of relevant protein markers for CRC.

CLINICAL COLORECTAL CANCER (2021)

Review Biochemistry & Molecular Biology

Opinion PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies

Christopher D. Nishimura, Marc C. Pulanco, Wei Cui, Liming Lu, Xingxing Zang

Summary: This article discusses the ligand-ligand cis-interaction between PD-L1 and B7-1 and its impact on immune checkpoint pathways, suggesting significant crosstalk between these pathways and providing new insights for immunotherapies and treatments.

TRENDS IN MOLECULAR MEDICINE (2021)

Article Oncology

B7 score and T cell infiltration stratify immune status in prostate cancer

Qianghua Zhou, Kaiwen Li, Yiming Lai, Kai Yao, Qiong Wang, Xiangyu Zhan, Shirong Peng, Wenli Cai, Wei Yao, Xingxing Zang, Kewei Xu, Jian Huang, Hai Huang

Summary: Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment in PCa. The B7 score, combined with CD8(+) TILs, can be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Immunology

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

Yao Wei, Xiaoxin Ren, Phillip M. Galbo, Scott Moerdler, Hao Wang, R. Alejandro Sica, Bijan Etemad-Gilbertson, Lei Shi, Liqiang Zhu, Xudong Tang, Qi Lin, Mou Peng, Fangxia Guan, Deyou Zheng, Jordan M. Chinai, Xingxing Zang

Summary: HHLA2 is a promising target for cancer immunotherapy due to its coinhibitory function and overexpression in human cancers. The KIR3DL3-HHLA2 pathway may be a potential immunotherapeutic target for cancer.

SCIENCE IMMUNOLOGY (2021)

Article Hematology

Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα

Ilseyar Akhmetzyanova, Tonya Aaron, Phillip Galbo, Anastasia Tikhonova, Igor Dolgalev, Masato Tanaka, Iannis Aifantis, Deyou Zheng, Xingxing Zang, David Fooksman

Summary: The dissemination and progression of multiple myeloma is associated with an increased inflammatory signature in bone marrow MPs, with CD169(+) MPs playing a critical role in the early spread of myeloma.

BLOOD ADVANCES (2021)

Article Multidisciplinary Sciences

The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy

Peter John, Marc C. Pulanco, Phillip M. Galbo, Yao Wei, Kim C. Ohaegbulam, Deyou Zheng, Xingxing Zang

Summary: B7x, an immune checkpoint molecule, promotes the conversion of CD4+ T cells into regulatory T cells within the tumor microenvironment. It induces transcriptomic changes in regulatory T cells, altering their phenotype to an activated and suppressive state. B7x-mediated regulation reduces the efficacy of anti-CTLA-4 treatment, but combination therapy with anti-B7x and anti-CTLA-4 overcomes this resistance and shows synergistic therapeutic efficacy.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development

Elodie Picarda, Phillip M. Galbo, Haihong Zong, Meenu Rohini Rajan, Ville Wallenius, Deyou Zheng, Emma Borgeson, Rajat Singh, Jeffrey Pessin, Xingxing Zang

Summary: The immune checkpoint B7-H3 has been studied in the tumor microenvironment and immunotherapy, but its potential role in metabolism remains largely unknown. This study reveals that B7-H3 is highly expressed in adipose tissue, particularly in adipocyte progenitor cells, and it regulates the glycolytic and mitochondrial activity of these cells. Loss of B7-H3 leads to impaired oxidative metabolism and increased lipid accumulation in derived adipocytes. Knockout of B7-H3 in mice results in spontaneous obesity, metabolic dysfunction, and adipose tissue inflammation.

SCIENCE ADVANCES (2022)

Review Immunology

Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Marc C. Pulanco, Anne T. Madsen, Ankit Tanwar, Devin T. Corrigan, Xingxing Zang

Summary: The B7/CD28 families of immune checkpoints play important roles in regulating immune cells and are closely related to various diseases. Recent studies have discovered new pathways and therapeutics for cancer therapy in this field. This review covers the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, metabolic regulation by PD-1/PD-L1 and B7-H3, the glycobiology of PD-1/PD-L1, B7x, and B7-H3, as well as the interaction between PD-L1 and B7-1. The article also discusses the resistance mechanisms to current immunotherapies targeting PD-1/PD-L1 and CTLA-4 in clinical settings, and reviews new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in ongoing clinical trials.

CELLULAR & MOLECULAR IMMUNOLOGY (2023)

Review Biochemistry & Molecular Biology

Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities

Xiaoxin Ren, Yixian Li, Christopher Nishimura, Xingxing Zang

Summary: Somatic activating mutations in EGFR are common in various cancers. Targeted therapies against EGFR have shown clinical efficacy, but acquired resistance is a challenge. PD-1/PD-L1 immune checkpoint inhibitors are effective in some cancers, but limited in EGFR mutated cancers. Up-regulation of new B7/CD28 family members related to EGFR signaling may contribute to immunosuppressive tumor microenvironment and resistance to EGFR-targeted therapies. Understanding these interactions could inform combination therapeutic strategies.

GENES & DISEASES (2022)

Article Oncology

LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma

Scott Moerdler, Michelle Ewart, Debra L. Friedman, Kara Kelly, Qinglin Pei, Mou Peng, XingXing Zang, Peter D. Cole

Summary: In pediatric Hodgkin lymphoma, LAG-3 expression is found to be positively correlated with PD-L1 expression, serving as an innovative immune checkpoint target with unclear association to patient outcomes.

LEUKEMIA & LYMPHOMA (2021)

No Data Available